318 related articles for article (PubMed ID: 19459041)
1. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
Billam M; Sobolewski MD; Davidson NE
Breast Cancer Res Treat; 2010 Apr; 120(3):581-92. PubMed ID: 19459041
[TBL] [Abstract][Full Text] [Related]
2. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity.
Kim HJ; Kim JH; Chie EK; Young PD; Kim IA; Kim IH
Radiat Oncol; 2012 Mar; 7():39. PubMed ID: 22429326
[TBL] [Abstract][Full Text] [Related]
3. The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells.
Ruiz-Magaña MJ; Rodríguez-Vargas JM; Morales JC; Saldivia MA; Schulze-Osthoff K; Ruiz-Ruiz C
Int J Cancer; 2012 Mar; 130(5):1195-207. PubMed ID: 21455989
[TBL] [Abstract][Full Text] [Related]
4. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
Fan J; Yin WJ; Lu JS; Wang L; Wu J; Wu FY; Di GH; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Aug; 134(8):883-90. PubMed ID: 18264725
[TBL] [Abstract][Full Text] [Related]
5. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine.
Champion C; Guianvarc'h D; Sénamaud-Beaufort C; Jurkowska RZ; Jeltsch A; Ponger L; Arimondo PB; Guieysse-Peugeot AL
PLoS One; 2010 Aug; 5(8):e12388. PubMed ID: 20808780
[TBL] [Abstract][Full Text] [Related]
8. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines.
Yan L; Nass SJ; Smith D; Nelson WG; Herman JG; Davidson NE
Cancer Biol Ther; 2003; 2(5):552-6. PubMed ID: 14614325
[TBL] [Abstract][Full Text] [Related]
9. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells.
Savickiene J; Treigyte G; Jonusiene V; Bruzaite R; Borutinskaite VV; Navakauskiene R
Mol Cell Biochem; 2012 Jan; 359(1-2):245-61. PubMed ID: 21842375
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
12. DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.
Nakamura K; Nakabayashi K; Htet Aung K; Aizawa K; Hori N; Yamauchi J; Hata K; Tanoue A
PLoS One; 2015; 10(3):e0120545. PubMed ID: 25799509
[TBL] [Abstract][Full Text] [Related]
13. Effect of Zebularine in Comparison to and in Combination with Trichostatin A on CIP/KIP Family (p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2), DNMTs (DNMT1, DNMT3a, and DNMT3b), Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) Gene Expression, Cell Growth Inhibition and Apoptosis Induction in Colon Cancer LS 174T Cell Line.
Sanaei M; Kavoosi F
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2131-2139. PubMed ID: 32711442
[TBL] [Abstract][Full Text] [Related]
14. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Hurtubise A; Momparler RL
Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
[TBL] [Abstract][Full Text] [Related]
15. Anti-Cancer Effects of Epigenetics Drugs Scriptaid and Zebularine in Human Breast Adenocarcinoma Cells.
Yap ZH; Kong WY; Azeez AR; Fang CM; Ngai SC
Anticancer Agents Med Chem; 2022; 22(8):1582-1591. PubMed ID: 34102995
[TBL] [Abstract][Full Text] [Related]
16. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.
Balch C; Yan P; Craft T; Young S; Skalnik DG; Huang TH; Nephew KP
Mol Cancer Ther; 2005 Oct; 4(10):1505-14. PubMed ID: 16227399
[TBL] [Abstract][Full Text] [Related]
17. Induction of the estrogen receptor by ablation of DNMT1 in ER-negative breast cancer cells.
Adams PD; Cairns P
Cancer Biol Ther; 2003; 2(5):557-8. PubMed ID: 14614326
[No Abstract] [Full Text] [Related]
18. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
Xu J; Huo D; Chen Y; Nwachukwu C; Collins C; Rowell J; Slamon DJ; Olopade OI
Breast Cancer Res Treat; 2010 Apr; 120(3):593-601. PubMed ID: 19466541
[TBL] [Abstract][Full Text] [Related]
19. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE
Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193
[TBL] [Abstract][Full Text] [Related]
20. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Luszczek W; Cheriyath V; Mekhail TM; Borden EC
Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
